Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022)
第一作者机构:[1]Peking Univ, Peking Univ Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Inst Hematol, 11 South St Xizhimen, Beijing 100044, Peoples R China
通讯作者:
通讯机构:[1]Peking Univ, Peking Univ Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Inst Hematol, 11 South St Xizhimen, Beijing 100044, Peoples R China[16]Beijing Key Lab Hematopoiet Stem Cell Transplanta, 11 South St Xizhimen, Beijing 100044, Peoples R China[17]Peking Tsinghua Ctr Life Sci, 11 South St Xizhimen, Beijing 100044, Peoples R China[18]Peking Univ, Acad Adv Interdisciplinary Studies, 11 South St Xizhimen, Beijing 100044, Peoples R China
推荐引用方式(GB/T 7714):
Jiang Qian,Li Zongru,Qin Yazhen,et al.Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022)[J].JOURNAL OF HEMATOLOGY & ONCOLOGY.2022,15(1):doi:10.1186/s13045-022-01369-2.
APA:
Jiang, Qian,Li, Zongru,Qin, Yazhen,Li, Weiming,Xu, Na...&Huang, Xiaojun.(2022).Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022).JOURNAL OF HEMATOLOGY & ONCOLOGY,15,(1)
MLA:
Jiang, Qian,et al."Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022)".JOURNAL OF HEMATOLOGY & ONCOLOGY 15..1(2022)